title: Hyperfibrinogenemia increases the risk of cardiac events after coronary artery stenting.
abstract: Primary success rates, and the angiographic and clinical outcome after percutaneous coronary intervention, are influenced by many different factors. Clinical features and morphologic characteristics of the target lesion are important. Also, interventionally caused endothelial trauma may trigger atherogenetic and procoagulatory factors leading to intraluminal thrombosis. The study population consisted of 228 consecutive, unselected patients with symptomatic coronary artery disease or exercise-induced myocardial ischemia and coronary artery stenoses eligible for percutaneous intervention. We analyzed different clinical, morphological, and laboratory (total cholesterol, high-density lipoprotein-cholesterol, low-density lipoprotein-cholesterol, triglycerides, fibrinogen) features in those patients with adverse cardiac events (stent thrombosis, myocardial infarction, urgent target vessel revascularization, death) after primary successful coronary artery stenting, compared with a control group without adverse events. In the group with adverse cardiac events we found a significantly higher level of fibrinogen compared with the control group. Other laboratory data and clinical characteristics were not significantly different between the two groups. The study shows a possible association between hyperfibrinogenemia and adverse cardiac events after intracoronary stenting. In clinical practice, the potential role of elevated levels of fibrinogen in an unfavorable outcome after percutaneous coronary interventions should be considered when planning coronary artery stenting.
authors.affiliation: Department of Cardiology and Angiology, Berufsgenossenschaftliche Kliniken Bergmannsheil, University of Bochum, Germany. alfried.germing@ruhr-uni-bochum.de
authors.forename: A
authors.initials: A
authors.lastname: Germing
authors.forename: S
authors.initials: S
authors.lastname: von Dryander
authors.forename: A
authors.initials: A
authors.lastname: Machraoui
authors.forename: W
authors.initials: W
authors.lastname: Bojara
authors.forename: T
authors.initials: T
authors.lastname: Lawo
authors.forename: P
authors.initials: P
authors.lastname: Grewe
authors.forename: J
authors.initials: J
authors.lastname: Barmeyer
authors.forename: B
authors.initials: B
authors.lastname: Lemke
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects; D002784:Cholesterol / Q000097:blood; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000097:blood / Q000150:complications / Q000401:mortality / Q000628:therapy*; D005260:Female; D005340:Fibrinogen / Q000032:analysis*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009203:Myocardial Infarction / Q000209:etiology; D012008:Recurrence; D012307:Risk Factors; D015607:Stents; D013927:Thrombosis / Q000209:etiology
chemical_list: D005340:Fibrinogen; D002784:Cholesterol